Quantity | = | Concentration | x | Volume | x | Molecular Weight |
---|---|---|---|---|---|---|
= | x | x |
1) Click the Molarity Calculation Cart® button.
2) Specify the Concentration and Volume of your desired Molarity.
3) Click Calculate.
4) Your desired Quantity will be calculated and will be put under Quantity: (only for mg)
5) Click Add to Cart and then Proceed to checkout to complete the order. You will receive the quantity as you ordered as solvent-free form.
Alert: If you want to make a solution with a solvent (such DMSO), please add instructions in the notes section (such as 10 nM/1 mL in DMSO) and we will pack and deliver the product as a solution (such as 10 nM solution in 1 mL DMSO). If the product cannot be dissolved in DMSO or you would like to specify your own preferred solvent, please add detailed instructions in the notes section. All solutions must be shipped with an ice bag, costing an additional fee of $20 for S&H.
AOB5345
CAS No:84-36-6
Chemical Name: (3β,16β,17α,18β,20α)-18-[[4-[(Ethoxycarbonyl)oxy]-3,5-dimethoxybenzoyl]oxy]-11,17-dimethoxy-yohimban-16-carboxylic acid methyl ester, Methyl reserpate ester of syringic acid ethyl carbonate
Warning: Last items in stock!
Availability date:
Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
---|---|---|---|
1 | 100 | $11.25 | Total: $1,125.00 |
1 | 50 | $13.00 | Total: $650.00 |
1 | 25 | $15.25 | Total: $381.25 |
1 | 10 | $18.00 | Total: $180.00 |
1 | 5 | $21.25 | Total: $106.25 |
Molecular Formula | C35H42N2O11 |
Molecular Weight | 666.71 |
CAS Numbers | 84-36-6 |
Storage Condition | 0°C (short term), -20°C (long term), desiccated |
Solubility | DMSO |
Purity | 98% by HPLC |
Synonym | Syrosingopine; HF-41T; SU 3118 |
IUPAC/Chemical Name | 3beta,20alpha-Yohimban-16beta-carboxylic acid, 18beta-hydroxy-11,17alpha-dimethoxy-, methyl ester, 4-hydroxy-3,5-dimethoxybenzoate (ester) ethyl carbonate (ester) (8CI) |
InChl Key | ZCDNRPPFBQDQHR-SSYATKPKSA-N |
InChl Code | InChI=1S/C35H42N2O11/c1-7-46-35(40)48-31-26(42-3)12-18(13-27(31)43-4)33(38)47-28-14-19-17-37-11-10-22-21-9-8-20(41-2)15-24(21)36-30(22)25(37)16-23(19)29(32(28)44-5)34(39)45-6/h8-9,12-13,15,19,23,25,28-29,32,36H,7,10-11,14,16-17H2,1-6H3/t19-,23+,25-,28-,29+,32+/m1/s1 |
SMILES Code | [H][C@@]12C(NC3=C4C=CC(OC)=C3)=C4CCN1C[C@]5(C[C@@H](OC(C6=CC(OC)=C(OC(OCC)=O)C(OC)=C6)=O)[C@H](OC)[C@@H](C(OC)=O)[C@]5(C2)[H])[H] |
References | 1) Palfai T, Walsh TJ. Comparison of the long-term cumulative effects of reserpine and syrosingopine on general activity. Pharmacol Biochem Behav. 1979 Nov;11(5):585-7. PubMed PMID: 43517. 2) Pham-Huu-Chanh, De Schaepdryver AF. On the pharmacology of syrosingopine and reserpine. Arch Int Pharmacodyn Ther. 1965 Sep;157(1):207-13. PubMed PMID: 4380062. 3) CALESNICK B. Reduced sedative effect of a newly synthesized reserpine derivative (syrosingopine): clinical appraisal in primary hypertension. J Am Geriatr Soc. 1959 Aug;7(8):648-55. PubMed PMID: 13672741. |
an antihypertensive drug